Although there is compelling evidence supporting IP therapy over multiple daily insulin injection for T1DM (8, 11), the availability of IP therapy around the world is extremely heterogeneous and is not often related to the country's economic status (12–14). This evidence concerns the gene INS and type 1 diabetes mellitus.